AR035745A1 - Bacteria gram-negativa, una composicion inmunogena, una composicion para vacunas, un metodo para producir un mutante, un polinucleotido de pasteurellaceae purificado y aislado, un vector, una celula transformada establemente o transfectada, metodo para producir un polipeptido recombinante, anticuerp - Google Patents
Bacteria gram-negativa, una composicion inmunogena, una composicion para vacunas, un metodo para producir un mutante, un polinucleotido de pasteurellaceae purificado y aislado, un vector, una celula transformada establemente o transfectada, metodo para producir un polipeptido recombinante, anticuerpInfo
- Publication number
- AR035745A1 AR035745A1 ARP020100402A ARP020100402A AR035745A1 AR 035745 A1 AR035745 A1 AR 035745A1 AR P020100402 A ARP020100402 A AR P020100402A AR P020100402 A ARP020100402 A AR P020100402A AR 035745 A1 AR035745 A1 AR 035745A1
- Authority
- AR
- Argentina
- Prior art keywords
- mutation
- seq
- nos
- set forth
- polypeptide
- Prior art date
Links
- 241000894006 Bacteria Species 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 4
- 241000606752 Pasteurellaceae Species 0.000 title abstract 2
- 239000013598 vector Substances 0.000 title abstract 2
- 229960005486 vaccine Drugs 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 abstract 7
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 7
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 7
- 230000035772 mutation Effects 0.000 abstract 6
- 108090000623 proteins and genes Proteins 0.000 abstract 6
- 230000000694 effects Effects 0.000 abstract 5
- 230000002068 genetic effect Effects 0.000 abstract 5
- 239000002773 nucleotide Substances 0.000 abstract 4
- 125000003729 nucleotide group Chemical group 0.000 abstract 4
- 241000894007 species Species 0.000 abstract 3
- 108020004414 DNA Proteins 0.000 abstract 2
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 235000015097 nutrients Nutrition 0.000 abstract 2
- 241000606860 Pasteurella Species 0.000 abstract 1
- 239000003242 anti bacterial agent Substances 0.000 abstract 1
- 230000002238 attenuated effect Effects 0.000 abstract 1
- 238000012258 culturing Methods 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/809,665 US6790950B2 (en) | 1999-04-09 | 2001-03-15 | Anti-bacterial vaccine compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR035745A1 true AR035745A1 (es) | 2004-07-07 |
Family
ID=25201919
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020100402A AR035745A1 (es) | 2001-03-15 | 2002-02-07 | Bacteria gram-negativa, una composicion inmunogena, una composicion para vacunas, un metodo para producir un mutante, un polinucleotido de pasteurellaceae purificado y aislado, un vector, una celula transformada establemente o transfectada, metodo para producir un polipeptido recombinante, anticuerp |
| ARP090101850A AR071888A2 (es) | 2001-03-15 | 2009-05-22 | Bacteria pasteurellaceae gram-negativa, una composicion inmunogena, una composicion para vacunas |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090101850A AR071888A2 (es) | 2001-03-15 | 2009-05-22 | Bacteria pasteurellaceae gram-negativa, una composicion inmunogena, una composicion para vacunas |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US6790950B2 (enExample) |
| EP (1) | EP1368456B1 (enExample) |
| JP (2) | JP2005502315A (enExample) |
| AR (2) | AR035745A1 (enExample) |
| AT (1) | ATE500316T1 (enExample) |
| AU (1) | AU2002240033B2 (enExample) |
| CA (2) | CA2438315C (enExample) |
| CY (1) | CY1112014T1 (enExample) |
| DE (1) | DE60239318D1 (enExample) |
| DK (1) | DK1368456T3 (enExample) |
| ES (1) | ES2362041T3 (enExample) |
| MX (1) | MXPA03008296A (enExample) |
| NZ (1) | NZ528208A (enExample) |
| PE (1) | PE20021008A1 (enExample) |
| PT (1) | PT1368456E (enExample) |
| SI (1) | SI1368456T1 (enExample) |
| TW (4) | TWI335935B (enExample) |
| WO (1) | WO2002075507A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6455323B1 (en) * | 1997-07-03 | 2002-09-24 | Pharmacia & Upjohn Company | Anti-bacterial methods and materials |
| US6790950B2 (en) * | 1999-04-09 | 2004-09-14 | Pharmacia & Upjohn Company | Anti-bacterial vaccine compositions |
| JP4892134B2 (ja) * | 1999-04-09 | 2012-03-07 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | 抗菌ワクチン組成物 |
| WO2002034771A2 (en) | 2000-10-27 | 2002-05-02 | Chiron Srl | Nucleic acids and proteins from streptococcus groups a & b |
| US7449178B2 (en) * | 2002-04-05 | 2008-11-11 | Merial Limited | Attenuated gram negative bacteria |
| US7794734B2 (en) * | 2002-10-30 | 2010-09-14 | The Board Of Regents For Oklahoma State University | Mannheimia haemolytica chimeric outer membrane protein PlpE and leukotoxin epitopes as a vaccine or vaccine component against shipping fever |
| GB0228691D0 (en) * | 2002-12-09 | 2003-01-15 | Imp College Innovations Ltd | Bacterial virulence genes |
| EP1648500B1 (en) | 2003-07-31 | 2014-07-09 | Novartis Vaccines and Diagnostics, Inc. | Immunogenic compositions for streptococcus pyogenes |
| US8945589B2 (en) | 2003-09-15 | 2015-02-03 | Novartis Vaccines And Diagnostics, Srl | Immunogenic compositions for Streptococcus agalactiae |
| US9107864B2 (en) * | 2004-06-07 | 2015-08-18 | Qu Biologics Inc. | Tissue targeted antigenic activation of the immune response to treat cancers |
| EP2073829B1 (en) * | 2006-10-05 | 2012-06-20 | New York Blood Center, Inc. | Stabilized therapeutic small helical antiviral peptides |
| US8937154B2 (en) | 2006-10-05 | 2015-01-20 | New York Blood Center, Inc. | Stabilized therapeutic small helical antiviral peptides |
| AU2008299376B2 (en) | 2007-09-12 | 2013-02-28 | Glaxosmithkline Biologicals S.A. | GAS57 mutant antigens and GAS57 antibodies |
| JP2011522796A (ja) | 2008-05-06 | 2011-08-04 | ニューヨーク ブラッド センター， インコーポレイテッド | 抗ウイルス細胞透過性ペプチド |
| CA2729818A1 (en) * | 2008-07-03 | 2010-01-07 | Biotechnology Research And Development Corporation | Vaccines comprising pasteurella multocida recombinant filamentous hemagglutinin peptides |
| CA2774636C (en) | 2009-09-25 | 2019-05-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to hiv-1 and their use |
| US20150044192A1 (en) | 2013-08-09 | 2015-02-12 | President And Fellows Of Harvard College | Methods for identifying a target site of a cas9 nuclease |
| US9757445B2 (en) | 2013-11-01 | 2017-09-12 | Merial Inc. | Attenuated Pasteurella multocida vaccines and methods of making and use thereof |
| CN116593695B (zh) * | 2022-12-29 | 2025-08-05 | 重庆澳龙生物制品有限公司 | 一种牛多杀性巴氏杆菌荚膜a型elisa抗体检测试剂盒及其制备方法和应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4735801A (en) | 1982-09-07 | 1988-04-05 | Board Of Trustees Of Leland Stanford Jr. University | Novel non-reverting salmonella live vaccines |
| US5077044A (en) | 1980-05-19 | 1991-12-31 | The Board Of Trustees Of The Leland Stanford Jr. University | Novel non-reverting shigella live vaccines |
| SE8205892D0 (sv) | 1982-10-18 | 1982-10-18 | Bror Morein | Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin |
| SE8405493D0 (sv) | 1984-11-01 | 1984-11-01 | Bror Morein | Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel |
| US4877612A (en) | 1985-05-20 | 1989-10-31 | Frank M. Berger | Immunological adjuvant and process for preparing the same, pharmaceutical compositions, and process |
| DK166762B1 (da) | 1986-01-14 | 1993-07-12 | Nederlanden Staat | Fremgangsmaade til fremstilling af immunogenkomplekser og farmaceutisk sammensaetning indeholdende saadanne komplekser |
| US4806352A (en) | 1986-04-15 | 1989-02-21 | Ribi Immunochem Research Inc. | Immunological lipid emulsion adjuvant |
| CA1340522C (en) | 1987-03-10 | 1999-05-04 | Heinz Dobeli | Fusion proteins containing neighbouring histidines for improved purification |
| IL86583A0 (en) | 1987-06-04 | 1988-11-15 | Molecular Eng Ass | Vaccine containing a derivative of a microbe and method for the production thereof |
| PL170938B1 (pl) | 1991-03-05 | 1997-02-28 | Wellcome Found | Sposób wytwarzania szczepionki przeciwko infekcjom Salmonella PL PL |
| US5840312A (en) | 1991-05-02 | 1998-11-24 | Institut Pasteur | Recombinant Bacillus anthracis strains unable to produce the lethal factor protein or edema factor protein |
| WO1994011024A1 (en) | 1992-11-06 | 1994-05-26 | Regents Of The University Of Minnesota | Composition protective against p. multocida pasteurellosis infection |
| US5585277A (en) | 1993-06-21 | 1996-12-17 | Scriptgen Pharmaceuticals, Inc. | Screening method for identifying ligands for target proteins |
| WO1995020652A1 (de) | 1994-01-28 | 1995-08-03 | Medigene Gmbh | Verfahren zur bestimmung der aktivität eines regulatorischen faktors sowie verwendung dieses verfahrens |
| KR100445103B1 (ko) | 1994-12-09 | 2004-12-04 | 임페리얼 컬리지 이노베이션스 리미티드 | 유전자의동정 |
| GB9518220D0 (en) | 1995-09-06 | 1995-11-08 | Medical Res Council | Checkpoint gene |
| BR9713195A (pt) * | 1996-09-06 | 1999-12-21 | Peter Ruhdal Jensen | Método de aperfeiçoamento da produção de biomassa ou de um produto desejado de uma célula. |
| US6673538B1 (en) * | 1997-07-25 | 2004-01-06 | The Trustees Of Boston University | Methods and compositions for designing vaccines |
| US6790950B2 (en) * | 1999-04-09 | 2004-09-14 | Pharmacia & Upjohn Company | Anti-bacterial vaccine compositions |
| JP4892134B2 (ja) | 1999-04-09 | 2012-03-07 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | 抗菌ワクチン組成物 |
| US6376211B1 (en) * | 1999-07-12 | 2002-04-23 | Xoma Technology Ltd. | Agents and methods for inhibiting F1/F0 ATPase |
| DE60124526D1 (de) * | 2000-04-27 | 2006-12-28 | Max Planck Gesellschaft | Methode zur identifizierung von helicobacter antigenen |
-
2001
- 2001-03-15 US US09/809,665 patent/US6790950B2/en not_active Expired - Lifetime
-
2002
- 2002-01-17 MX MXPA03008296A patent/MXPA03008296A/es active IP Right Grant
- 2002-01-17 CA CA2438315A patent/CA2438315C/en not_active Expired - Lifetime
- 2002-01-17 CA CA2852293A patent/CA2852293A1/en not_active Abandoned
- 2002-01-17 ES ES02705915T patent/ES2362041T3/es not_active Expired - Lifetime
- 2002-01-17 EP EP02705915A patent/EP1368456B1/en not_active Expired - Lifetime
- 2002-01-17 AU AU2002240033A patent/AU2002240033B2/en not_active Expired
- 2002-01-17 NZ NZ528208A patent/NZ528208A/en not_active IP Right Cessation
- 2002-01-17 DE DE60239318T patent/DE60239318D1/de not_active Expired - Lifetime
- 2002-01-17 DK DK02705915.3T patent/DK1368456T3/da active
- 2002-01-17 WO PCT/US2002/001971 patent/WO2002075507A2/en not_active Ceased
- 2002-01-17 JP JP2002574050A patent/JP2005502315A/ja active Pending
- 2002-01-17 AT AT02705915T patent/ATE500316T1/de active
- 2002-01-17 SI SI200230939T patent/SI1368456T1/sl unknown
- 2002-01-17 PT PT02705915T patent/PT1368456E/pt unknown
- 2002-02-07 AR ARP020100402A patent/AR035745A1/es not_active Application Discontinuation
- 2002-02-08 TW TW099122913A patent/TWI335935B/zh not_active IP Right Cessation
- 2002-02-08 TW TW099122912A patent/TWI335934B/zh not_active IP Right Cessation
- 2002-02-08 TW TW091102640A patent/TWI328035B/zh not_active IP Right Cessation
- 2002-02-08 TW TW097148939A patent/TWI334884B/zh not_active IP Right Cessation
- 2002-02-27 PE PE2002000160A patent/PE20021008A1/es not_active Application Discontinuation
-
2004
- 2004-05-26 US US10/854,299 patent/US7476391B2/en not_active Expired - Lifetime
-
2009
- 2009-05-22 AR ARP090101850A patent/AR071888A2/es unknown
-
2010
- 2010-11-04 JP JP2010247585A patent/JP2011097938A/ja active Pending
-
2011
- 2011-04-18 CY CY20111100401T patent/CY1112014T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002075507A2 (en) | 2002-09-26 |
| TW201040261A (en) | 2010-11-16 |
| ATE500316T1 (de) | 2011-03-15 |
| TWI334884B (en) | 2010-12-21 |
| NZ528208A (en) | 2008-04-30 |
| DE60239318D1 (de) | 2011-04-14 |
| CA2438315C (en) | 2014-09-02 |
| EP1368456B1 (en) | 2011-03-02 |
| MXPA03008296A (es) | 2007-05-28 |
| TWI328035B (en) | 2010-08-01 |
| JP2005502315A (ja) | 2005-01-27 |
| US20050003512A1 (en) | 2005-01-06 |
| AU2002240033B2 (en) | 2007-11-08 |
| PT1368456E (pt) | 2011-06-01 |
| SI1368456T1 (sl) | 2011-06-30 |
| CY1112014T1 (el) | 2015-11-04 |
| JP2011097938A (ja) | 2011-05-19 |
| US20040110268A1 (en) | 2004-06-10 |
| US6790950B2 (en) | 2004-09-14 |
| CA2438315A1 (en) | 2002-09-26 |
| ES2362041T3 (es) | 2011-06-27 |
| PE20021008A1 (es) | 2002-11-13 |
| DK1368456T3 (da) | 2011-05-23 |
| WO2002075507B1 (en) | 2003-12-11 |
| AR071888A2 (es) | 2010-07-21 |
| TW200916577A (en) | 2009-04-16 |
| CA2852293A1 (en) | 2002-09-26 |
| TWI335935B (en) | 2011-01-11 |
| TW201040262A (en) | 2010-11-16 |
| WO2002075507A3 (en) | 2003-09-12 |
| TWI335934B (en) | 2011-01-11 |
| US7476391B2 (en) | 2009-01-13 |
| EP1368456A2 (en) | 2003-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR035745A1 (es) | Bacteria gram-negativa, una composicion inmunogena, una composicion para vacunas, un metodo para producir un mutante, un polinucleotido de pasteurellaceae purificado y aislado, un vector, una celula transformada establemente o transfectada, metodo para producir un polipeptido recombinante, anticuerp | |
| Christensen et al. | Establishment of new genetic traits in a microbial biofilm community | |
| Merritt et al. | Motility and chemotaxis in Agrobacterium tumefaciens surface attachment and biofilm formation | |
| CN106062203B (zh) | 宿主细胞修饰的方法 | |
| Morita et al. | Cell wall-anchored nuclease of Streptococcus sanguinis contributes to escape from neutrophil extracellular trap-mediated bacteriocidal activity | |
| Gahan et al. | The use of listeriolysin to identify in vivo induced genes in the gram‐positive intracellular pathogen Listeria monocytogenes | |
| SA93130462B1 (ar) | طوافر mutants مزالة السمية مولدة للمناعة من سم الكوليرا ومن سم غير ثابت حراريا , تحضيرها واستحدامها لتحضير اللقاحات | |
| Choi et al. | Enhanced production of recombinant proteins with Corynebacterium glutamicum by deletion of insertion sequences (IS elements) | |
| CN104837984A (zh) | 宿主细胞修饰方法 | |
| AR029622A1 (es) | Una bacteria pasteurellaceae gram-negativa que comprende una mutacion en un gen, una composicion inmunogenica, una composicion de vacuna, un metodo para producir una mutante de dicha bacteria, un metodo para producir dicha bacteria atenuada, un polinucleotido purificado y aislado de la misma, un vec | |
| EP3262061B1 (en) | Peptides for facilitating secretion and uses thereof | |
| JP6161190B2 (ja) | 耐熱性ケラチナーゼ酵素、その製造方法、およびそれをコードするｄｎａ | |
| Qian et al. | Genome-scale mutagenesis and phenotypic characterization of two-component signal transduction systems in Xanthomonas campestris pv. campestris ATCC 33913 | |
| JP2005502315A5 (enExample) | ||
| Filiatrault et al. | Construction and characterization of Haemophilus ducreyi lipooligosaccharide (LOS) mutants defective in expression of heptosyltransferase III and β1, 4-glucosyltransferase: identification of LOS glycoforms containing lactosamine repeats | |
| Silakowski et al. | fbfB, a gene encoding a putative galactose oxidase, is involved in Stigmatella aurantiaca fruiting body formation | |
| Bannam et al. | Mutagenesis of active-site histidines of Listeria monocytogenes phosphatidylinositol-specific phospholipase C: effects on enzyme activity and biological function | |
| CN114616348A (zh) | 皮革改性剂 | |
| Bereswill et al. | The ferric uptake regulator (Fur) homologue of Helicobacter pylori: functional analysis of the coding gene and controlled production of the recombinant protein in Escherichia coli | |
| HUT53154A (en) | Process for producing protease-defective gram-positive bacteria and utilizing them as host-organizmus for producing recombinant products | |
| JP2001510037A (ja) | グラム陽性微生物からのプロテアーゼ | |
| US20160304845A1 (en) | New dna cleavage enzyme | |
| JP2005517435A (ja) | 新規の真菌リパーゼ | |
| CA2385132A1 (en) | Process for producing ubiquinone-10 | |
| Bereswill et al. | Hemolytic properties and riboflavin synthesis of Helicobacter pylori: cloning and functional characterization of the rib A gene encoding GTP-cyclohydrolase II that confers hemolytic activity to Escherichia coli |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |